The epidermal growth factor receptor family in breast cancer

por Koutras, Angelos K, Evans, T R Jeffry
Publicado 2008

Virotherapy: cancer gene therapy at last?

por Bilsland, Alan E., Spiliopoulou, Pavlina, Evans, T. R. Jeffry
Publicado 2016

Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review

por Glen, Claire, Tan, Yun Yi, Waterston, Ashita, Evans, Thomas R. Jeffry, Jones, Robert J., Petrie, Mark C., Lang, Ninian N.
Publicado 2022

Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma

por Briggs, Andrew, Daniele, Bruno, Dick, Katherine, Evans, Thomas R. Jeffry, Galle, Peter R., Hubner, Richard A., Lopez, Carlos, Siebert, Uwe, Tremblay, Gabriel
Publicado 2020

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

por Propper, David, Jones, Keith, Anthoney, D. Alan, Mansoor, Wasat, Ford, Daniel, Eatock, Martin, Agarwal, Roshan, Inatani, Michiyasu, Saito, Tomohisa, Abe, Masaichi, Evans, T. R. Jeffry
Publicado 2016

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

por Twelves, Chris, Anthoney, Alan, Savulsky, Claudio I., Guo, Matthew, Reyderman, Larisa, Cresti, Nicola, Semiglazov, Vladimir, Timcheva, Constanta, Zubairi, Ishtiaq, Morrison, Rosemary, Plummer, Ruth, Evans, T. R. Jeffry
Publicado 2019

Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma

por Evans, Thomas R. Jeffry, Kudo, Masatoshi, Finn, Richard S., Han, Kwang-Hyub, Cheng, Ann-Lii, Ikeda, Masafumi, Kraljevic, Silvija, Ren, Min, Dutcus, Corina E., Piscaglia, Fabio, Sung, Max W.
Publicado 2019

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular...

por Evans, Thomas R. Jeffry, Kudo, Masatoshi, Finn, Richard S., Han, Kwang-Hyub, Cheng, Ann-Lii, Ikeda, Masafumi, Kraljevic, Silvija, Ren, Min, Dutcus, Corina E., Piscaglia, Fabio, Sung, Max W.
Publicado 2019

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

por Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca
Publicado 2019

Liquid Biopsy for Pancreatic Cancer Detection Using Infrared Spectroscopy

por Sala, Alexandra, Cameron, James M., Jenkins, Cerys A., Barr, Hugh, Christie, Loren, Conn, Justin J. A., Evans, Thomas R. Jeffry, Harris, Dean A., Palmer, David S., Rinaldi, Christopher, Theakstone, Ashton G., Baker, Matthew J.
Publicado 2022

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

por Motzer, Robert J., Taylor, Matthew H., Evans, Thomas R. Jeffry, Okusaka, Takuji, Glen, Hilary, Lubiniecki, Gregory M., Dutcus, Corina, Smith, Alan D., Okpara, Chinyere E., Hussein, Ziad, Hayato, Seiichi, Tamai, Toshiyuki, Makker, Vicky
Publicado 2022

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

por Kristeleit, Rebecca, Plummer, Ruth, Jones, Robert, Carter, Louise, Blagden, Sarah, Sarker, Debashis, Arkenau, Tobias, Evans, Thomas R. Jeffry, Danson, Sarah, Symeonides, Stefan N., Veal, Gareth J., Klencke, Barbara J., Kowalski, Mark M., Banerji, Udai
Publicado 2023

LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest

por Morton, Jennifer P., Jamieson, Nigel B., Karim, Saadia A., Athineos, Dimitris, Ridgway, Rachel A., Nixon, Colin, McKay, Colin J., Carter, Ross, Brunton, Valerie G., Frame, Margaret C., Ashworth, Alan, Oien, Karin A., Evans, T.R. Jeffry, Sansom, Owen J.
Publicado 2010

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

por Hamid, Omid, Hassel, Jessica C, Shoushtari, Alexander N, Meier, Friedegund, Bauer, Todd M, Salama, April K S, Kirkwood, John M, Ascierto, Paolo A, Lorigan, Paul C, Mauch, Cornelia, Orloff, Marlana, Evans, Thomas R Jeffry, Holland, Chris, Edukulla, Ramakrishna, Abedin, Shaad E, Middleton, Mark R
Publicado 2023

A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection

por Annese, Valerio F., Patil, Samadhan B., Hu, Chunxiao, Giagkoulovits, Christos, Al-Rawhani, Mohammed A., Grant, James, Macleod, Martin, Clayton, David J., Heaney, Liam M., Daly, Ronan, Accarino, Claudio, Shah, Yash D., Cheah, Boon C., Beeley, James, Evans, Thomas R. Jeffry, Jones, Robert, Barrett, Michael P., Cumming, David R. S.
Publicado 2021

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

por Finn, Richard S., Kudo, Masatoshi, Cheng, Ann-Lii, Wyrwicz, Lucjan, Ngan, Roger K.C., Blanc, Jean-Frederic, Baron, Ari D., Vogel, Arndt, Ikeda, Masafumi, Piscaglia, Fabio, Han, Kwang-Hyub, Qin, Shukui, Minoshima, Yukinori, Kanekiyo, Michio, Ren, Min, Dairiki, Ryo, Tamai, Toshiyuki, Dutcus, Corina E., Ikezawa, Hiroki, Funahashi, Yasuhiro, Evans, Thomas R. Jeffry
Publicado 2021

Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study

por Solovyeva, Olga, Dimairo, Munyaradzi, Weir, Christopher J., Hee, Siew Wan, Espinasse, Aude, Ursino, Moreno, Patel, Dhrusti, Kightley, Andrew, Hughes, Sarah, Jaki, Thomas, Mander, Adrian, Evans, Thomas R. Jeffry, Lee, Shing, Hopewell, Sally, Rantell, Khadija Rerhou, Chan, An-Wen, Bedding, Alun, Stephens, Richard, Richards, Dawn, Roberts, Lesley, Kirkpatrick, John, de Bono, Johann, Yap, Christina
Publicado 2023

Targeting mTOR dependency in pancreatic cancer

por Morran, Douglas C, Wu, Jianmin, Jamieson, Nigel B, Mrowinska, Agata, Kalna, Gabriela, Karim, Saadia A, Au, Amy Y M, Scarlett, Christopher J, Chang, David K, Pajak, Malgorzata Z, Oien, Karin A, McKay, Colin J, Carter, C Ross, Gillen, Gerry, Champion, Sue, Pimlott, Sally L, Anderson, Kurt I, Evans, T R Jeffry, Grimmond, Sean M, Biankin, Andrew V, Sansom, Owen J, Morton, Jennifer P
Publicado 2014

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

por Miller, Bryan W, Morton, Jennifer P, Pinese, Mark, Saturno, Grazia, Jamieson, Nigel B, McGhee, Ewan, Timpson, Paul, Leach, Joshua, McGarry, Lynn, Shanks, Emma, Bailey, Peter, Chang, David, Oien, Karin, Karim, Saadia, Au, Amy, Steele, Colin, Carter, Christopher Ross, McKay, Colin, Anderson, Kurt, Evans, Thomas R Jeffry, Marais, Richard, Springer, Caroline, Biankin, Andrew, Erler, Janine T, Sansom, Owen J
Publicado 2015

Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule

por Marchetti, Chiara, Zyner, Katherine G., Ohnmacht, Stephan A., Robson, Mathew, Haider, Shozeb M., Morton, Jennifer P., Marsico, Giovanni, Vo, Tam, Laughlin-Toth, Sarah, Ahmed, Ahmed A., Di Vita, Gloria, Pazitna, Ingrida, Gunaratnam, Mekala, Besser, Rachael J., Andrade, Ana C. G., Diocou, Seckou, Pike, Jeremy A., Tannahill, David, Pedley, R. Barbara, Evans, T. R. Jeffry, Wilson, W. David, Balasubramanian, Shankar, Neidle, Stephen
Publicado 2018